Question · asked by 1 review
RAS inhibitors vs CCBs: End‐stage renal disease
- Population
- patients with hypertension
- Intervention
- RAS inhibitors
- Comparison
- CCBs
- Outcome
- End‐stage renal disease
RAS inhibitors showed no clear difference in end stage renal failure compared with CCBs (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
RAS inhibitors vs CCBs End stage renal failure · people with hypertension RAS inhibitors showed no clear difference in end stage renal failure compared with CCBs (low certainty). First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug… (2018) · Cochrane Headline outcomes only | RR 0.88 [0.74, 1.05] | 4 studies · 19551 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for hypertension 2018 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- RAS inhibitors vs thiazides · patients with hypertension · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.